drugset / Trial / NCT02762045
Clinical Trial of Recombinant Adenovirus Type 5 AIDS Vaccine
Phase 1
Unknown
36 enrolled
Centers for Disease Control and Prevention, China
Beijing Ditan Hospital · collabNational Institutes for Food and Drug Control, China · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
This is a randomized, double-blind placebo-controlled dose-escalation clinical trial to evaluate the safety and the immunogenicity of Adenoviral vector 5 HIV-1 vaccines in subjects receiving stable highly active antiretroviral therapy(HAART) .
Timeline
- Start
- 2016-04
- Primary completion
- 2016-12
- Completion
- 2017-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ad5-gag | Unknown | 2e+09 unknown | — |
| Subject | Ad5-gag | Unknown | 2e+10 unknown | — |
| Subject | Ad5-gag | Unknown | 2e+11 unknown | — |